Table 1.
Comparison of treatments and clinical and pathological characteristics of tumors according to age at breast cancer diagnosis.
| Variables | Total | Q1(22-43years) | Q2(44-50years) | Q3(51-58years) | Q4(59-90years) | P-value |
|---|---|---|---|---|---|---|
| Number of patients | 1054 | 248 | 245 | 271 | 290 | |
| AGE (years) | 51.00 (44.00-59.00) | 39.00 (36.00-41.00) | 47.00 (45.00-49.00) | 54.00 (52.00-56.00) | 64.50 (61.00-70.00) | <0.001 |
| T category [n (%)] | 0.149 | |||||
| Tis | 22 (2.09%) | 7 (2.82%) | 5 (2.04%) | 3 (1.11%) | 7 (2.41%) | |
| T1 | 452 (42.88%) | 98 (39.52%) | 107 (43.67%) | 118 (43.54%) | 129 (44.48%) | |
| T2 | 467 (44.31%) | 105 (42.34%) | 105 (42.86%) | 124 (45.76%) | 133 (45.86%) | |
| T3 | 62 (5.88%) | 18 (7.26%) | 14 (5.71%) | 19 (7.01%) | 11 (3.79%) | |
| T4 | 2 (0.19%) | 0 (0.00%) | 0 (0.00%) | 1 (0.37%) | 1 (0.34%) | |
| Unknown | 49 (4.65%) | 20 (8.06%) | 14 (5.71%) | 6 (2.21%) | 9 (3.10%) | |
| N category [n (%)] | 0.290 | |||||
| N0 | 592 (56.17%) | 133 (53.63%) | 133 (54.29%) | 158 (58.30%) | 168 (57.93%) | |
| N1 | 257 (24.38%) | 64 (25.81%) | 57 (23.27%) | 64 (23.62%) | 72 (24.83%) | |
| N2 | 119 (11.29%) | 33 (13.31%) | 36 (14.69%) | 27 (9.96%) | 23 (7.93%) | |
| N3 | 66 (6.26%) | 12 (4.84%) | 17 (6.94%) | 19 (7.01%) | 18 (6.21%) | |
| Unknown | 20 (1.90%) | 6 (2.42%) | 2 (0.82%) | 3 (1.11%) | 9 (3.10%) | |
| Stage of TNM | 0.541 | |||||
| 0 | 25 (2.37%) | 8 (3.23%) | 7 (2.86%) | 3 (1.11%) | 7 (2.41%) | |
| 1 | 280 (26.57%) | 58 (23.39%) | 64 (26.12%) | 74 (27.31%) | 84 (28.97%) | |
| 2 | 482 (45.73%) | 116 (46.77%) | 103 (42.04%) | 125 (46.13%) | 138 (47.59%) | |
| 3 | 206 (19.54%) | 49 (19.76%) | 53 (21.63%) | 57 (21.03%) | 47 (16.21%) | |
| Unknown | 61 (5.79%) | 17 (6.85%) | 18 (7.35%) | 12 (4.43%) | 14 (4.83%) | |
| Tumor size(cm) | 0.159 | |||||
| <2cm | 463 (43.93%) | 101 (40.73%) | 111 (45.31%) | 119 (43.91%) | 132 (45.52%) | |
| >2cm | 538 (51.04%) | 127 (51.21%) | 120 (48.98%) | 144 (53.14%) | 147 (50.69%) | |
| Unknown | 53 (5.03%) | 20 (8.06%) | 14 (5.71%) | 8 (2.95%) | 11 (3.79%) | |
| Histopathological grade | 0.163 | |||||
| Low intermediate (G1, G2) | 617 (58.54%) | 132 (53.23%) | 149 (60.82%) | 160 (59.04%) | 176 (60.69%) | |
| High, G3 | 258 (24.48%) | 72 (29.03%) | 54 (22.04%) | 73 (26.94%) | 59 (20.34%) | |
| Unknown | 179 (16.98%) | 44 (17.74%) | 42 (17.14%) | 38 (14.02%) | 55 (18.97%) | |
| LN N (%) | 0.695 | |||||
| Negative | 591 (56.07%) | 134 (54.03%) | 134 (54.69%) | 154 (56.83%) | 169 (58.28%) | |
| Positive | 439 (41.65%) | 108 (43.55%) | 108 (44.08%) | 111 (40.96%) | 112 (38.62%) | |
| Unknown | 24 (2.28%) | 6 (2.42%) | 3 (1.22%) | 6 (2.21%) | 9 (3.10%) | |
| Molecular subtype | 0.165 | |||||
| Luminal A | 256 (24.29%) | 55 (22.18%) | 61 (24.90%) | 56 (20.66%) | 84 (28.97%) | |
| Luminal B (HER-2-) | 374 (35.48%) | 84 (33.87%) | 93 (37.96%) | 100 (36.90%) | 97 (33.45%) | |
| HER-2+ (HR*+) | 122 (11.57%) | 32 (12.90%) | 28 (11.43%) | 40 (14.76%) | 22 (7.59%) | |
| HER-2+ (HR*-) | 133 (12.62%) | 27 (10.89%) | 29 (11.84%) | 40 (14.76%) | 37 (12.76%) | |
| Triple negative | 120 (11.39%) | 36 (14.52%) | 22 (8.98%) | 25 (9.23%) | 37 (12.76%) | |
| Unknown | 49 (4.65%) | 14 (5.65%) | 12 (4.90%) | 10 (3.69%) | 13 (4.48%) | |
| Ki-67 level | 0.002 | |||||
| <14% | 294 (27.89%) | 65 (26.21%) | 62 (25.31%) | 67 (24.72%) | 100 (34.48%) | |
| 14%≤1 ≤ 30% | 402 (38.14%) | 81 (32.66%) | 91 (37.14%) | 116 (42.80%) | 114 (39.31%) | |
| >30% | 311 (29.51%) | 87 (35.08%) | 78 (31.84%) | 83 (30.63%) | 63 (21.72%) | |
| Unknown | 47 (4.46%) | 15 (6.05%) | 14 (5.71%) | 5 (1.85%) | 13 (4.48%) | |
| ER status | 0.055 | |||||
| Negative | 289 (27.42%) | 67 (27.02%) | 56 (22.86%) | 81 (29.89%) | 85 (29.31%) | |
| Positive | 753 (71.44%) | 174 (70.16%) | 188 (76.73%) | 188 (69.37%) | 203 (70.00%) | |
| Unknown | 12 (1.14%) | 7 (2.82%) | 1 (0.41%) | 2 (0.74%) | 2 (0.69%) | |
| PR status | 0.010 | |||||
| Negative | 396 (37.57%) | 87 (35.08%) | 76 (31.02%) | 116 (42.80%) | 117 (40.34%) | |
| Positive | 643 (61.01%) | 153 (61.69%) | 167 (68.16%) | 152 (56.09%) | 171 (58.97%) | |
| Unknown | 15 (1.42%) | 8 (3.23%) | 2 (0.82%) | 3 (1.11%) | 2 (0.69%) | |
| HER-2 status | 0.188 | |||||
| Negative | 758 (71.92%) | 179 (72.18%) | 179 (73.06%) | 178 (65.68%) | 222 (76.55%) | |
| Positive | 252 (23.91%) | 58 (23.39%) | 57 (23.27%) | 80 (29.52%) | 57 (19.66%) | |
| Unknown | 44 (4.17%) | 11 (4.44%) | 9 (3.67%) | 13 (4.80%) | 11 (3.79%) | |
| Operation type | 0.001 | |||||
| BCS | 170 (16.13%) | 56 (22.58%) | 42 (17.14%) | 44 (16.24%) | 28 (9.66%) | |
| M | 884 (83.87%) | 192 (77.42%) | 203 (82.86%) | 227 (83.76%) | 262 (90.34%) | |
| Adjuvant therapy | 0.002 | |||||
| Chemotherapy | 476 (45.16%) | 121 (48.79%) | 123 (50.20%) | 128 (47.23%) | 104 (35.86%) | |
| Radiotherapy | 34 (3.23%) | 8 (3.23%) | 7 (2.86%) | 7 (2.58%) | 12 (4.14%) | |
| Both | 262 (24.86%) | 61 (24.60%) | 63 (25.71%) | 71 (26.20%) | 67 (23.10%) | |
| None | 282 (26.76%) | 58 (23.39%) | 52 (21.22%) | 65 (23.99%) | 107 (36.90%) | |
| Hormonal therapy N (%) | 0.254 | |||||
| No | 419 (39.75%) | 100 (40.32%) | 89 (36.33%) | 102 (37.64%) | 128 (44.14%) | |
| Yes | 635 (60.25%) | 148 (59.68%) | 156 (63.67%) | 169 (62.36%) | 162 (55.86%) | |
| Follow-up time (years) | 4.86(3.26-6.83) | 4.90(3.42-6.86) | 5.01 (3.63-7.10) | 4.53 (3.06-6.80) | 4.85 (3.19-6.55) | 0.115 |
median and Q1-Q3 for continuous variables; Number (%) for categorical variables; T, tumor size; N, lymph nodes; ER, estrogen receptor; PR: progesterone receptor; HER-2, human epidermal growth factor receptor 2; BCS, breast-conserving surgery; M, mastectomy; LN, lymph nodes in the axilla status.
The bold values denote statistical significance at P<0.05 level.